Crescendo Biologics announces publication in Neoplasia of preclinical tumour penetration data supporting CB307

Crescendo Biologics announces publication in Neoplasia of preclinical tumour penetration data supporting CB307 Cambridge, UK, 12 February 2024 – Crescendo Biologics Ltd (Crescendo), a clinical stage, immuno- oncology company developing novel, targeted T cell enhancing therapeutics, today announces the publication of a paper in the peer-reviewed journal Neoplasia. The paper, ‘Impact of tissue penetration and albumin binding on design of T cell targeted bispecific agents’, resulted from a collaboration between Crescendo’s scientists and Greg Thurber’s laboratory at the University of Michigan. To determine the impact of tissue penetration on the activity of bispecific agents, the authors studied Crescendo’s CD137 x PSMA, a half-life extended bispecific, derived from the company’s Humabody® VH platform. The data, from PSMA-positive preclinical models, demonstrate the following: • Crescendo’s half-life extended CD137 x PSMA bispecific showed superior tumour penetration compared to full-length monoclonal antibodies directed towards PSMA • Efficient tumour penetration correlates with enhanced target access and T cell activation Dr Kenji Hashimoto, Chief Medical Officer at Crescendo Biologics, commented: “The data generated by the team at the University of Michigan further validates CB307’s potential in a clinical setting. The POTENTIA trial of CB307 in patients with prostate cancer is progressing well, and we look forward to the maturation of our Phase 1b clinical results.” -Ends- For more information, please contact: Crescendo Biologics ICR Consilium Theodora Harold, CEO + 44 (0) 12 2349 7140 [email protected] [email protected] Mary-Jane Elliott, David Daley, Sukaina Virji [email protected] About CB307 CB307 is Crescendo’s lead clinical candidate, a first-in-class, half-life extended, CD137 x PSMA bispecific Humabody®, designed to deliver a safer and more durable anti-cancer T cell response. CB307 conditionally activates only tumour-specific T cells, exclusively within the tumour microenvironment using the CD137 co-stimulatory mechanism. Its unique format enables potent, tumour-specific killing, while avoiding systemic toxicity and can be applied to a broad range of PSMA+ cancer indications to address a large unmet medical need. Clinical development of CB307 is on track with the Phase 1b POTENTIA trial ongoing in adult patients with PSMA+ metastatic castration-resistant prostate cancer (mCRPC). POTENTIA (NCT04839991) is an open- label, dose escalation and cohort expansion study to assess the safety, tolerability and preliminary efficacy of CB307 as a monotherapy and in combination with pembrolizumab (KEYTRUDA®). About Crescendo Biologics Crescendo Biologics is a private, clinical-stage immuno-oncology company developing novel, targeted T cell-enhancing therapeutics derived from its proprietary Humabody® VH platform. Beyond Crescendo’s proprietary pipeline, the Company has global, multi-target discovery and development collaborations with Takeda and BioNTech, and an exclusive worldwide licensing agreement with Zai Lab. Located in Cambridge, UK, Crescendo is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, BioNTech, Takeda, Quan Capital and Kreos Capital. Visit www.crescendobiologics.com and follow on LinkedIn and X (Twitter).

The release as fetched from its publisher. crescendobiologics.com ↗